Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer

By Yahoo! Finance | Sep 10, 2024 at 02:30 PM EST

Bayer received $14 million upfront for mosliciguat, a lung-targeted sGC activator. Pulmovant presented promising Phase 1b data at the ERS Congress. The drug showed significant reductions in pulmonary vascular resistance, indicating potential for treating PH-ILD patients.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.